RxDoctor Payments Data

Anne Peters, MD

Endocrinology, Diabetes & Metabolism · Beverly Hills, CANPI 1376572784

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $85,861 of the $121,362 with a category attached, or 70.7%. 26 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Reporting peaked in 2019 at $44,486 and has fallen 93.0% since, to $3,130 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$121,362in general payments, 2019–2025

Across 203 payments — averaging $597.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$31K
  • Abbott$19K
  • Eli Lilly$19K
  • Mannkind Corporation$15K
  • Boehringer Ingelheim$9K
  • Zealand Pharma US, Inc.$9K
  • plus $19K from 20 others
$445,877in research payments, 2019–2025

Across 56 payments — averaging $7962.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dexcom, Inc.$293K
  • Insulet Corporation$141K
  • Sanofi-aventis U.S. LLC$7K
  • Abbott$5K

What the payments were for

  • Consulting fees$85,86171%
  • Speaking & faculty fees$26,99622%
  • Travel & lodging$4,1743%
  • Food & beverage$4,2894%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,362 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$89,155
Medicare patients
236
Services billed
1,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide297$382,948
MounjaroTirzepatide189$201,626
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7105$142,007
JardianceEmpagliflozin101$102,171
JanuviaSitagliptin Phosphate53$65,259
Tresiba Flextouch U-100Insulin Degludec95$60,529
HumalogInsulin Lispro110$34,107
Xultophy 100-3.6Insulin Degludec/Liraglutide25$33,551
TradjentaLinagliptin44$28,178
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$22,332
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt16$21,756
FarxigaDapagliflozin Propanediol28$19,786
AfrezzaInsulin Regular, Human24$14,494
TrulicityDulaglutide14$13,600
Lantus SolostarInsulin Glargine,hum.Rec.Anlog85$11,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Novolog$30,853$426,232346 claims
Lilly USA, LLCMounjaro, Humalog, Trulicity$87$249,333313 claims
Boehringer IngelheimJardiance, Tradjenta$9,457$130,349145 claims
MerckJanuvia$2,125$65,25953 claims
AstraZenecaFarxiga$58$19,78628 claims
Mannkind CorporationAfrezza$15,062$14,49424 claims
AbbVieSynthroid$50$4,91068 claims
Sanofi-aventis U.S. LLCLantus$75$1,92124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →